Huapont Life Sciences Co.Ltd(002004) 3 on the evening of March 18, the annual report of 2021 was released. In 2021, the company achieved an operating revenue of 12.359 billion yuan, a year-on-year increase of 13.63%; The net profit attributable to the shareholders of the listed company was 670 million yuan, a year-on-year increase of 2.81%; The basic earnings per share is 0.34 yuan. The company plans to distribute a cash dividend of 2.2 yuan (including tax) to all shareholders for every 10 shares.
The annual report shows that in 2021, the company firmly implemented the "great health" development strategy of medicine and medical treatment, and continued to improve the whole industry chain development model integrating API, preparation, functional skin care products, pan skin health management and medical services. In terms of medicine, strengthen the research and development of new products and product layout, consolidate the company's leading position in the prescription market, and actively explore the retail market outside the hospital; Launch a variety of functional skin care products and skin medical devices to further extend the pan skin health industry chain; Make use of the surplus production capacity to actively develop cdmo business of APIs and preparations.
In terms of medical treatment, Kuanren hospital in northern Chongqing continued to maintain rapid development, with an annual revenue of 295 million yuan, a year-on-year increase of 2.8 times. Its discipline structure was further improved, the number of visits increased steadily and the medical level was continuously improved; Beijing Huasheng rehabilitation hospital has been successfully opened. At present, it has been included in the designated medical institutions of Beijing medical insurance. In the follow-up, it will further improve the discipline construction and cultivate the talent echelon to achieve better development. The agrochemical and new materials sectors were separated and listed respectively. Yingtai biology moved from the selection layer to the Beijing stock exchange and Shandong Kaisheng New Materials Co.Ltd(301069) was issued and listed on the gem of Shenzhen Stock Exchange. From the perspective of business structure, the company further clarified its business layout and realized light loading.
During the reporting period, the company continued to increase R & D investment. Rivaroxaban tablets, mesalazine enteric coated granules and tadalafil tablets (5mg / 10mg) were successively approved. Methylprednisolone sodium succinate for injection (40mg / 500mg) and ambroxol hydrochloride injection passed the consistency evaluation. On the existing basis, the company further improved the structure of skin, tuberculosis and anti-tumor products, expanded the category coverage, and contributed new performance growth points to the company.
In the business plan, the company said that it would establish three to five pharmaceutical products every year, concentrate resources to ensure the rapid approval of products under research, and orderly promote the consistency evaluation of stock products; Strengthen the marketing outside the hospital, continuously introduce varieties into the retail market, and further expand the brand influence. For Kuanren hospital and Watson rehabilitation hospital, focus on medical treatment and scientific research, improve the discipline system, cultivate high-quality medical teams, and promote the two hospitals to become a regional high-level comprehensive medical platform; Export mature medical technology and management system to empower private hospitals; Combining resources inside and outside the hospital, incubate innovative projects, and actively develop specialized centers and consumer medical business.
